Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GPC Biotech has reported preclinical data on RGB-286638, the company's multi-targeted protein kinase inhibitor, that supported the potential utility of RGB-286638 against some hematological malignancies.
Subscribe to our email newsletter
The data demonstrated that the RGB-286638 small molecule has potent activity against chronic myeloid leukemia (CML) in in vivo models that are resistant to imatinib (Gleevec) and to dasatinib (Sprycel), the current standards of care for treating this form of cancer.
Additionally, RGB-286638 has been shown in vitro to be active against a number of families of protein kinases that are important for the proliferation of cancer cells, said GPC Biotech. RGB-286638 is expected to enter Phase I clinical testing this year.
Martine George, senior vice president of drug development and chief medical officer of GPC Biotech, said: “We are particularly excited to see the strong effect that RGB-286638 has against Gleevec- or Sprycel-resistant tumor cells. These data are supportive of our clinical plans for RGB-286638: we expect to initiate a Phase I trial in solid tumors in the near future, followed by a study in hematological tumors, including CML, during 2009.”